FY2024 Earnings Estimate for HRMY Issued By HC Wainwright

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Harmony Biosciences in a note issued to investors on Tuesday, December 17th. HC Wainwright analyst P. Trucchio anticipates that the company will earn $2.63 per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.36 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2024 earnings at $0.97 EPS, Q1 2025 earnings at $0.80 EPS, Q2 2025 earnings at $0.93 EPS, Q3 2025 earnings at $1.03 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $3.85 EPS, FY2026 earnings at $5.49 EPS, FY2027 earnings at $6.61 EPS and FY2028 earnings at $7.03 EPS.

A number of other research firms have also weighed in on HRMY. Oppenheimer restated an “outperform” rating and issued a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Raymond James reissued an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Mizuho lifted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research report on Tuesday, October 29th. Finally, UBS Group assumed coverage on Harmony Biosciences in a research note on Tuesday, September 10th. They set a “buy” rating and a $56.00 price objective on the stock. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.80.

Harmony Biosciences Stock Up 1.2 %

Harmony Biosciences stock opened at $33.89 on Friday. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 0.60 and a beta of 0.79. The firm’s fifty day moving average price is $34.25 and its two-hundred day moving average price is $34.07. Harmony Biosciences has a 1-year low of $28.14 and a 1-year high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The company had revenue of $186.00 million for the quarter, compared to analysts’ expectations of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period last year, the business earned $0.63 EPS.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 30.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Harmony Biosciences

Several large investors have recently modified their holdings of HRMY. nVerses Capital LLC bought a new position in Harmony Biosciences during the second quarter valued at $36,000. CWM LLC lifted its position in shares of Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after buying an additional 775 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Harmony Biosciences during the 3rd quarter worth $74,000. Quarry LP purchased a new stake in Harmony Biosciences in the 2nd quarter worth about $62,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after acquiring an additional 360 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.